GlassScriptPhysician profile
Sarah J Denham
NPI 1275832784
$4,499.04
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $596 · 2021: $1,247 · 2022: $904 · 2023: $882 · 2024: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,294.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.09 | 2019-2024 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $599.09 | 2019-2024 | Otezla, Repatha, Prolia |
| Novo Nordisk INC | $410.14 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $287.66 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $241.95 | 2019-2022 | |
| Pfizer INC. | $226.94 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $210.88 | 2020-2022 | |
| Lilly USA, LLC | $160.77 | 2019-2023 | Trulicity, Mounjaro |
| Merck Sharp & Dohme LLC | $160.55 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Otsuka America Pharmaceutical, INC. | $145.82 | 2022-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $131.47 | 2022-2024 | |
| Amarin Pharma, INC. | $99.45 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $89.85 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $80.97 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.05 | 2020-2023 | Trintellix |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Denham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.